ADAM SHORTS: Open Payments
NPI 1457825879 · SPRINGFIELD, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,489 in 93 payments from 18 companies in 2025. Trend: 2023 $588 · 2024 $884 · 2025 $1,489
Food & beverage: $1,488Education: $1
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $315 |
| Axsome Therapeutics, Inc. | 6 | $183 |
| AstraZeneca Pharmaceuticals LP | 8 | $167 |
| Vanda Pharmaceuticals Inc. | 10 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $136 |
| Lilly USA, LLC | 4 | $68 |
| Corium, LLC | 6 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $56 |
| Amgen Inc. | 3 | $51 |
| Novo Nordisk Inc | 3 | $50 |
Products named: Auvelity, FANAPT, QULIPTA, CAPLYTA, VRAYLAR, AIRSUPRA, Azstarys, FARXIGA.
Industry payments across LA — which companies pay providers there.
